Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Glyburide

FDA-approved product (tablet, oral), marketed as Diabeta, Glyburide, Glyburide (Micronized) and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Glyburide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diabetes mellitus
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sulfonylureas
FDA pharmacologic class
Sulfonylurea FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae11.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Glyburide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Glyburide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis

    NCT07221799 · start 2026-09-01

    Registered record
    Registry ID
    NCT07221799
    Conditions
    Multiple Sclerosis; Neuropathic Pain
    Interventions
    glibenclamide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-09-01
    Completion
    2029-09-01
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis; Neuropathic Pain
    Interventionglibenclamide; Placebo
    PhasePhase 1
    Registry statusNot yet recruiting

  • Glycaemic & Cardiovascular Treatment Outcomes of Voglibose Vs Glibenclamide Added to Metformin in T2DM Patients

    NCT05688332 · start 2023-08

    Registered record
    Registry ID
    NCT05688332
    Conditions
    Diabetes Mellitus Type 2 Without Complication
    Interventions
    Voglibose + Metformin; Glibenclamide + Metformin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2023-08
    Completion
    2024-01
    Enrolment
    118

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus Type 2 Without Complication
    InterventionVoglibose + Metformin; Glibenclamide + Metformin
    PhasePhase 3
    Registry statusUnknown

  • Oral Glibenclamide in Preterm Infants With Hyperglycaemia (GALOP)

    NCT05687500 · start 2023-05-20

    Registered record
    Registry ID
    NCT05687500
    Conditions
    Transient; Hypoglycemia, Neonatal; Preterm; Glibenclamide Adverse Reaction
    Interventions
    Glibenclamide; Pharmacokinetics study; C-peptide proinsulin ratio; Routine biological monitoring
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-05-20
    Completion
    2026-04-30
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransient; Hypoglycemia, Neonatal; Preterm; Glibenclamide Adverse Reaction
    InterventionGlibenclamide; Pharmacokinetics study; C-peptide proinsulin ratio; Routine biological monitoring
    PhasePhase 2
    Registry statusActive not recruiting

  • Spinal Cord Injury Neuroprotection With Glyburide

    NCT05426681 · start 2022-07-07

    Registered record
    Registry ID
    NCT05426681
    Conditions
    Acute Spinal Cord Injury
    Interventions
    GlyBURIDE Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2022-07-07
    Completion
    2028-05
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Spinal Cord Injury
    InterventionGlyBURIDE Oral Tablet
    PhasePhase 1
    Registry statusRecruiting

  • A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects

    NCT04859452 · start 2021-05-26

    Registered record
    Registry ID
    NCT04859452
    Conditions
    Healthy Subjects
    Interventions
    DBPR108 tablets; Metformin hydrochloride tablets; Glibenclamide tablets; Valsartan Capsules; Simvastatin tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-05-26
    Completion
    2021-07-09
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionDBPR108 tablets; Metformin hydrochloride tablets; Glibenclamide tablets; Valsartan Capsules +1 more
    PhasePhase 1
    Registry statusCompleted

  • The Hemodynamic Effects of PACAP38 After Glibenclamide Administration in Healthy Volunteers

    NCT04960657 · start 2020-10-20

    Registered record
    Registry ID
    NCT04960657
    Conditions
    Migraine; Headache; Pain
    Interventions
    glibenclamide; PACAP38
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-10-20
    Completion
    2021-03-19
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine; Headache; Pain
    Interventionglibenclamide; PACAP38
    PhaseNot applicable
    Registry statusCompleted

  • The Hemodynamics Effect of Glibenclamide on Levcromakalim Assessed by High Resolution Magnetic Resonance Angiography (MRA) Technique in a Randomized Double-blind Cross-over Placebo-controlled Study With Healthy Volunteers

    NCT03886922 · start 2019-04-01

    Registered record
    Registry ID
    NCT03886922
    Conditions
    Hemodynamics of Cranial Arteries; Headache; Cerebral Blood Flow
    Interventions
    Levcromakalim; Saline
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-04-01
    Completion
    2023-08-30
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHemodynamics of Cranial Arteries; Headache; Cerebral Blood Flow
    InterventionLevcromakalim; Saline
    PhaseNot applicable
    Registry statusUnknown

  • Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction

    NCT02864953 · start 2018-08-29

    Registered record
    Registry ID
    NCT02864953
    Conditions
    Brain Edema; Stroke, Acute
    Interventions
    BIIB093; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2018-08-29
    Completion
    2023-08-18
    Enrolment
    535

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain Edema; Stroke, Acute
    InterventionBIIB093; Placebo
    PhasePhase 3
    Registry statusTerminated

  • Glibenclamide in Aneurysmatic Subarachnoid Hemorrhage

    NCT03569540 · start 2018-07-03

    Registered record
    Registry ID
    NCT03569540
    Conditions
    Subarachnoid Hemorrhage, Aneurysmal
    Interventions
    Glibenclamide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2018-07-03
    Completion
    2019-12-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSubarachnoid Hemorrhage, Aneurysmal
    InterventionGlibenclamide; Placebo
    PhasePhase 4
    Registry statusUnknown

  • A Bioequivalence Study of Glibenclamide From Glibesyn 5 mg Tablets (Medochemie LTD Cyprus) and Daonil 5 mg Tablets (Sanofi-Aventis Cyprus Ltd. )

    NCT03855306 · start 2018-06-30

    Registered record
    Registry ID
    NCT03855306
    Conditions
    Healthy
    Interventions
    Glibesyn; Daonil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-06-30
    Completion
    2018-08-15
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionGlibesyn; Daonil
    PhasePhase 1
    Registry statusCompleted

  • Metabolic Analysis for Treatment Choice in Gestational Diabetes Mellitus

    NCT03029702 · start 2018-02-28

    Registered record
    Registry ID
    NCT03029702
    Conditions
    Gestational Diabetes; Diabetes, Gestational; Pregnancy in Diabetes
    Interventions
    Insulin; Glyburide; Metformin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-02-28
    Completion
    2023-08-31
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGestational Diabetes; Diabetes, Gestational; Pregnancy in Diabetes
    InterventionInsulin; Glyburide; Metformin
    PhasePhase 4
    Registry statusCompleted

  • Safety and Efficacy of Glibenclamide Combined With Rt-PA in Acute Cerebral Embolism

    NCT03284463 · start 2018-01-01

    Registered record
    Registry ID
    NCT03284463
    Conditions
    Acute Stroke
    Interventions
    Glibenclamide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2018-01-01
    Completion
    2023-05-28
    Enrolment
    306

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Stroke
    InterventionGlibenclamide; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Glyburide vs Placebo as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases (RAD 1502/UAB 1593)

    NCT02460874 · start 2017-08-16

    Registered record
    Registry ID
    NCT02460874
    Conditions
    Cerebral Edema; Brain Metastases
    Interventions
    Glyburide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2017-08-16
    Completion
    2021-05-19
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCerebral Edema; Brain Metastases
    InterventionGlyburide; Placebo
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Failure Rate of GLyburide And Metformin Among Gestational Diabetics

    NCT03078725 · start 2017-06-20

    Registered record
    Registry ID
    NCT03078725
    Conditions
    Gestational Diabetes Mellitus, Class A2
    Interventions
    Glyburide; Metformin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2017-06-20
    Completion
    2018-05-10
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGestational Diabetes Mellitus, Class A2
    InterventionGlyburide; Metformin
    PhasePhase 4
    Registry statusWithdrawn

  • Spinal Cord Injury Neuroprotection With Glyburide

    NCT02524379 · start 2017-02-14

    Registered record
    Registry ID
    NCT02524379
    Conditions
    Acute Spinal Cord Injury
    Interventions
    Glyburide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2017-02-14
    Completion
    2021-02-08
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Spinal Cord Injury
    InterventionGlyburide
    PhasePhase 1 / Phase 2
    Registry statusTerminated